Value-Based Oncology®: September 2022

Key stakeholders involved in the delivery of cancer care in New Jersey discuss strategies driving innovation in oncology and remaining challenges impeding their integration at the 70th Annual Roy A. Bowers Pharmaceutical Conference.

With 6 pegfilgrastim biosimilars approved, and multiple administration options, a patient-centric model of pegfilgrastim administration should be possible for patients with cancer who require prophylaxis of febrile neutropenia.

On September 7, a trio of panels from Avalere Health addressed steps that will follow approval of the Inflation Reduction Act, implementing the Enhancing Oncology Model (EOM) in 2023, and addressing health care disparities.

An updated national coverage determination from CMS about lung cancer screening has some stakeholders concerned that the quality of decision-making tools used by providers and patients may weaken.

A tool used to identify primary concerns of patients was helpful in identifying main worries about time, as it related to quality of life (QOL), and held value for patients and clinicians.

Patients were more likely to accept intervention from a psychologist if they received regular questionnaires.

At a panel for the National Health Alliance, 3 experts talked about incorporating patient needs and requests in cancer care.